New-onset autoimmune disease after COVID-19

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 8, 2024

Introduction Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) may trigger autoimmune disease (AD) through initial innate immune activation with subsequent aberrations in adaptive cells leading to AD. While there are multiple reports of incident AD diagnosed after COVID-19, the risk context key circulating strains is unknown. Methods TriNetX, a global, federated, health research network providing access electronic medical records across 74 healthcare organizations, was utilized define an adult cohort between January 1, 2020, and March 3, 2023. Exposure defined as COVID-19 diagnosis (ICD-10 code or positive laboratory test). Age- sex-propensity score-matched controls never had diagnosed. Outcomes were assessed 1 month year index date. Patients prior within date excluded from primary analysis. Incidence ratios each assessed. Results A total 3,908,592 patients included. Of 24 assessed, adjusted for eight who higher compared those no COVID-19. Cutaneous vasculitis (adjusted hazard ratio (aHR): 1.82; 95% CI 1.55–2.13), polyarteritis nodosa (aHR: 1.76; 1.15–2.70), hypersensitivity angiitis 1.64; 1.12–2.38) highest ratios. Overall, psoriasis (0.15%), rheumatoid arthritis (0.14%), type diabetes (0.13%) incidence during study period, these, more likely The any lower if when Omicron variants predominant strains. antinuclear antibody predictive Discussion SARS-CoV-2 be potential some AD, but decrease time given apparent infection variants.

Language: Английский

---

Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: April 2, 2024

We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) determine profile of polymyalgia rheumatica (PMR) giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on French database, we estimated RR PMR GCA cases individuals aged over 50 who developed their initial symptoms within one month receiving BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2.S vaccines. then nationwide survey gather profiles, therapeutic management, follow-up data from registered study. A total 70 854 684 COVID-19 vaccine doses were administered 25 260 485 adults, among which, 179 (RR 7. 1 cases/1 000 persons) 54 2. have been reported. The allowed characterization 60 35 cases. Median time onset first was 10 (range 2–30) 7 2–25) days for GCA, respectively. Phenotype, GCA-related ischemic complications -large vessel vasculitis as well management seemed similar according number shots received when compared literature unvaccinated population. Although rare, short between immunization suggests temporal association. Physician should be aware this potential vaccine-related phenomenon.

Language: Английский

---

Paradigm of immune dysregulation in coronavirus disease-2019 infection

Exploration of Immunology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 33

Published: Jan. 31, 2024

The coronavirus disease 2019 (COVID-19) pandemic cost 7–8 million deaths worldwide, creating an unprecedented health and economic crisis. Affecting 700 people globally, the magnitude of this is far from anything that humanity has encountered in recent times. A detailed investigation revealed more than severe acute respiratory syndrome 2 (SARS-CoV-2) virus, hyperactive immune system mediated injury as real cause mortality. Cytokine storm following viral infection leads to surge proinflammatory cytokines resulting distress (ARDS) lung injury. Anti-inflammatory intervention with anti-interleukin-6 (anti-IL-6) receptor monoclonal antibodies (mAbs; e.g., sarilumab tocilizumab) anti-IL-6 mAbs (i.e., siltuximab) and/or steroid-based approach substantial protection prevent death thereby implying role inflammation COVID-19. In review, authors have summarized dysregulated COVID-19 infection, investigating detail virus-host cross talks presenting possibilities therapeutic intervention.

Language: Английский

---

Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies

Journal of Autoimmunity, Journal Year: 2024, Volume and Issue: 148, P. 103299 - 103299

Published: Aug. 2, 2024

Language: Английский

---

COVID-19 on patients with immune-mediated rheumatic disease: a comparative study of disease activity, fatigue, and psychological distress over six months

Advances in Rheumatology, Journal Year: 2025, Volume and Issue: 65(1)

Published: Jan. 22, 2025

Abstract Objectives To compare the impact of COVID-19 on clinical status and psychological distress patients with immune-mediated rheumatic disease (IMRD) caused by SARS-CoV-2 infection that noninfected IMRD controls during a 6-month follow-up period. Methods The ReumaCoV Brazil is longitudinal study designed to follow for 6 months after (patients) compared without (controls). Clinical data, activity measurements current treatments regarding outcomes were evaluated in all patients. Disease was assessed through validated tools at inclusion 3 post-COVID-19. Fatigue, using FACIT-F (Functional Assessment Chronic Illness Therapy) distress, DASS 21 (Depression, Anxiety Stress Scale − Items), used both groups. significance level set as p < 0.05, 95% confidence interval. Results A total 601 evaluated—321 (IMRD + patients) 280 COVID-19- patients)—who predominantly female similar median ages. assessment over showed no significant difference between cases controls. Although mean scores did not differ significantly, some reported worsened post-COVID-19, particularly rheumatoid arthritis (RA) (32.2%) systemic lupus erythematosus (SLE) (23.3%). Post-COVID-19 worsening RA correlated medical global (MGA) CDAI scores, moderate large effect size. Diabetes mellitus positive association (OR = 7.15), while TNF inhibitors had protective 0.51). depression, anxiety, stress significantly greater than Worse post-COVID-19 worse DASS-21 No associations found activity, or DASS-21. Conclusions exhibited fatigue, stress, which can be mistaken despite having scores. variability reports flares potential triggering autoimmune manifestations underscore need detailed comprehensive approach managing them.

Language: Английский

---

Are rheumatology field professionals scientifically prepared to rehabilitate using exercise? A cross-sectional survey

Journal of Bodywork and Movement Therapies, Journal Year: 2025, Volume and Issue: 43, P. 124 - 129

Published: April 17, 2025

Language: Английский

---

From infection to autoimmunity: can COVID-19 spark new auto-immune Conditions?

Respiratory Medicine Case Reports, Journal Year: 2025, Volume and Issue: 55, P. 102216 - 102216

Published: Jan. 1, 2025

Language: Английский

---

Disproportionality analysis of European safety reports on autoimmune and rheumatic diseases following COVID-19 vaccination

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 27, 2025

Abstract The safety profile of COVID-19 vaccines is well-established, yet the widespread immunization campaign has led to an increase in reported cases Immune-Mediated and Rheumatic Diseases (IMDRs). This study aimed assess reporting Adverse Events Following Immunization (AEFIs) related IMDRs after vaccination. We analyzed all individual case reports (ICSRs) authorized European Union (i.e., tozinameran, elasomeran, ChAdOx1-S NCoV-19, Ad26.Cov2.S) registered EudraVigilance (EV) database from January 1, 2021, October 23, 2023. Our analysis identified ICSRs with events indicative conducted disproportionality Reporting Odds Ratio (ROR) 95% CI) examine frequency different IMDR types linked each vaccine. In total, 45,352 at least one AEFI associated rheumatic or autoimmune conditions, 54% them implicating tozinameran as suspected More than half AEFIs were classified serious, approximately 45% remaining unresolved. most frequently conditions other immune-mediated diseases, followed by arthritis, vasculitis, systemic lupus erythematosus, tendinopathies. suggested that mRNA may be more new diseases. Stratified revealed significant associations for ChAd, particularly vasculitis tendinopathies, only when compared Ad26.Cov2.S. Real-world pharmacovigilance data suggest diseases under-reported following vaccination, highlighting need further research better understand underlying mechanisms. findings this studies investigate these results greater depth.

Language: Английский

---

Risk of new-onset polymyalgia rheumatica following COVID-19 vaccination in South Korea: a self-controlled case-series study

RMD Open, Journal Year: 2025, Volume and Issue: 11(2), P. e005138 - e005138

Published: April 1, 2025

Background While several studies have reported some cases of polymyalgia rheumatica (PMR) following COVID-19 vaccination, using large databases are lacking. Objectives To investigate the risk PMR after vaccination self-controlled case series (SCCS) analysis Methods We used National Health Insurance Database, linked with registry between February 2021 and August 2023, to identify adults aged 50 years or older who received at least one dose vaccine subsequently diagnosed within observation period, defined as 240 days first vaccine. The window was 28 each control encompassed remainder period. Incidence rate ratios (IRRs) were estimated conditional Poisson regression 95% CIs, stratified by type. Results Among 44 818 078 recipients, 376 patients PMR. indicated that not associated an increased (IRR, 0.74; CI 0.59 0.94). Rather, slightly reduced (0.52; 0.34 0.79), no significant association other doses (0.83; 1.16 for second dose, 0.77, 0.48 1.25 third dose). Conclusion In this nationwide SCCS, there vaccination. these findings support safety vaccines, interpretation decreased should be cautious.

Language: Английский

---

Investigating the association between SARS-CoV-2 infection, COVID-19 vaccination, and autoimmune diseases in a pediatric population: a comprehensive analysis

Pediatric Rheumatology, Journal Year: 2025, Volume and Issue: 23(1)

Published: May 14, 2025

During the COVID-19 pandemic there were reports of an increased association between COVID 19 and various autoimmune diseases (AID) in adults. This study aims to investigate incidence AIDs children before during explores potential links SARS-CoV-2 vaccination. We analyzed 493,705 anonymized medical records from Maccabi Healthcare Services, Israel's second-largest healthcare provider, AID 2014-2022. The period was divided into three phases: two pre-pandemic phases equal duration (A B) a phase (C). Of 4,596 (0.9%) patients diagnosed with cohort, rates 0.9% for Group A (2014-2016), 1.0% B (2017-2019), C (2020-2022) (p = 0.13). Logistic regression showed no significant differences overall disease pre-COVID periods. Notably, specific conditions like celiac reduced (OR 0.8309, p 0.0071) while arthritis significantly more common Groups B. Additionally, diagnosis not associated risk (HR 1.092, 0.491); however, receiving at least one vaccine linked higher 1.2323, 0.0033). Our findings suggest that new-onset remained relatively stable pandemic. indicates vaccination developing diseases, necessitating further research elucidate long-term effects pediatric population.

Language: Английский

---